top of page
Screen Shot 2021-01-07 at 1.52_edited.jpg
PulseMedica logo

A Vision Without Eye Disease

PulseMedica is developing the first safe, effective, and non-invasive platform to screen and treat vitreoretinal disease, starting with symptomatic vitreous opacities (eye floaters).

PulseMedica Imaging Device Hero Web.jpg
Backed by Leading Investors

Recent News

May 29, 2024

PulseMedica Raises $12 Million CAD to Advance Eye Floater Imaging and Treatment Technology

PulseMedica Raises $12 Million CAD to Advance Eye Floater Imaging and Treatment Technology
PulseMedica Platform Solution for Floaters 3 Web.jpg

Our Mission

PulseMedica is laser focused on improving the quality of life for millions of people by building revolutionary technology to image and treat vitreoretinal disease.

Millions Worldwide Suffering from Eye Disease

Conditions such as vitreous floaters, age-related macular degeneration (AMD), diabetic retinopathy, and vitreomacular traction affect hundreds of millions of people worldwide.

Eye Injection PulseMedica Web.jpg

The Impact of Eye Floaters

52% of adults have floaters, where 5-10% of those impacted experience severe impairments and have no safe and non-invasive treatment options.

  • Vision Impairments

  • Anxiety 

  • Stress

  • Depression

  • Reduced Quality of Life

Mild, moderate, and severe impairments from floaters.

The Need For  Floater Treatment

There is a significant unmet need for a safe, effective and non-invasive office-based device to screen, diagnose, and treat eye floaters.

PulseMedica Platform Solution for Floaters 2 Web.jpg

Platform Technology

High-Resolution Real Time Imaging
Enhanced Laser Accuracy & Safety
Automated Treatment & Planning

Image Guided Laser Treatment

PulseMedica Retina Web.jpg

PulseMedica News and Updates

Latest developments, investments, and breakthroughs in our journey

May 29, 2024

PulseMedica Raises $12 Million CAD to Advance Eye Floater Imaging and Treatment Technology

PulseMedica Raises $12 Million CAD to Advance Eye Floater Imaging and Treatment Technology

By Taproot

2024

PulseMedica is Laser-Focused on Tackling Vitreoretinal Diseases

By Taproot

2024

AICE Validate Program Success Story

By Taproot

2022

PulseMedica closes $2.6M seed round
More PulseMedica Updates and News Content
logo_final.png

PulseMedica is Hiring, Join Our Team!

New Opportunities:

Software Quality Assurance Manager
Program Manager, Medical Device R&D
Full-Stack Software Developer
bottom of page